Zepbound multi-dose KwikPen becomes available

Eli Lilly said on Feb. 23, 2026, that the U.S. Food and Drug Administration approved a label expansion for Zepbound (tirzepatide) to include a four-dose, single-patient-use KwikPen that delivers a full month of treatment in one device ^[1]. Patients with a valid prescription who pay out of pocket through LillyDirect can now get any Zepbound dose as either a KwikPen or a single-dose vial at the same self-pay price, starting at $299 per month for the 2.5 mg starting dose ^[1].

The KwikPen is available in all six Zepbound strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[1][2]. On LillyDirect, the listed self-pay prices are $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg when a prescription is refilled within 45 days under the Zepbound Journey Program ^[2]. If a refill falls outside that 45-day window, regular prices apply: $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg ^[2]. Those are the same prices listed for the single-dose vials ^[2].

The difference is what arrives in the box. Lilly defines a self-pay "month" for the KwikPen as 28 days and one single-patient-use KwikPen, versus 28 days and four single-dose vials for the vial option ^[2]. Pen needles must be purchased separately with the KwikPen, and needles and syringes must be purchased separately with vials ^[2]. That is different from Zepbound's older single-dose pen, which includes a needle in each pen and is listed with insurance pricing as low as $25 per month for up to a three-month prescription for eligible patients ^[2].

Access channels also differ. LillyDirect lists the KwikPen as accepting select insurance as well as self-pay, with free delivery and pickup available, while the single-dose vial is described as exclusively available through LillyDirect and self-pay only ^[2]. Lilly also points eligible Medicare Part D patients with a Zepbound KwikPen prescription for weight management to its Medicare GLP-1 Bridge program ^[2]. Which specific insurance plans cover the KwikPen is not spelled out in the sources.

Lilly framed the launch as an access play. The company said more than 1 million patients used LillyDirect for its treatments in 2025, and that one of every three new patients starting a branded weight-management medicine in 2025 was prescribed Zepbound self-pay vials ^[1]. It said its self-pay pricing is a 50% or greater discount compared with the list price of other incretin (GLP-1) medicines for obesity ^[1].

Why it matters for patients

For people paying cash, this is a packaging and convenience change, not a price change. The self-pay cost per month is the same whether the medicine comes in one multi-dose pen or four vials ^[1][2]. What changes is handling: one device to store and track for four weekly doses instead of four vials plus separate syringes, though pen needles still have to be bought separately ^[2].

The pen also carries its own safety language. Lilly's labeling warns that a KwikPen should not be shared with other people even if the pen needle has been changed, because sharing can pass serious infections between users ^[1]. That warning matters more with a multi-dose device that stays in use for about a month.

Zepbound's other details are unchanged. It is approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, and for adults with moderate-to-severe obstructive sleep apnea and obesity ^[1]. The 2.5 mg strength is a starting dose and is not an approved maintenance dose; maintenance doses are 5 mg, 10 mg or 15 mg weekly for weight reduction, and 10 mg or 15 mg for sleep apnea ^[1]. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, belching, hair loss and heartburn ^[1]. The drug carries a boxed warning about thyroid C-cell tumors ^[1].

In trials, adults taking 15 mg in SURMOUNT-1 lost an average of 20.9% of body weight over 72 weeks versus 3.1% on placebo ^[1]. In the open-label SURMOUNT-5 trial, people on a maximum tolerated Zepbound dose lost an average of 20.2% (50 pounds) compared with 13.7% (33 pounds) for injectable Wegovy (semaglutide) ^[1].

What happens next

The KwikPen is described as available by prescription now through LillyDirect ^[1]. The sources do not say whether the KwikPen will reach retail pharmacies beyond that channel, how storage requirements differ from vials, or when broader insurance coverage might follow. Those points are not yet known.